Using cost-effectiveness analysis to sharpen formulary decision-making: The example of tiotropium at the veterans affairs health care system

Value in Health

Volumn 11, Issue 5, 2008, Pages 980-988

  Onukwugha, Ebere ^a   Mullins, C Daniel ^a   DeLisle, Sylvain ^b,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Chronic obstructive pulmonary disease; Cost effectiveness; Formulary decision making; Tiotropium; Veterans population

Indexed keywords

IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; PLACEBO; TIOTROPIUM BROMIDE;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DISEASE SEVERITY; DRUG COST; HEALTH CARE SYSTEM; HOSPITALIZATION; HUMAN; INFORMATION PROCESSING; MEDICAL RECORD REVIEW; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VETERAN;

EID: 52649134595     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2007.00314.x     Document Type: Article

References (19)

1. Mauskopf J, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices - budget impact analysis. Value Health 2007 10 : 336 47.
2. Levinson M, Chagan L. Tiotropium bromide for the maintenance of chronic obstructive pulmonary disease. P&T Journal 2004 29 : 490 4.
3. Somand H, Remington TL. Tiotropium: a bronchodilator for chronic obstructive pulmonary disease. Ann Pharmacother 2005 39 : 1467 75.
4. Sin DD, McAlister FA, Man SF, et al. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003 290 : 2301 12.
5. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2004 Update: Executive summary, global strategy for diagnosis, management and prevention of COPD (Based on April 1998 NHLBI/WHO Workshop). Available from: http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intld=1388 [Accessed December 7, 2007].
6. Jaen Diaz JI, de Castro MC, Cordero GB, et al. Effectiveness of treatment of tiotropium in patients who suffer from COPD. Med Clin (Barc) 2005 124 : 1 3.
7. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005 143 : 317 26.
8. Wagner T, Velez J, Chen S, et al. HERC's Inpatient Average Cost Datasets for VA Care 1998-2004. Menlo Park, CA : Health Economics Resource Center, Department of Veterans Affairs, 2005.
9. Maryland Health Care Consortium. Hospital Outpatient Spending. Baltimore MD : Maryland Health Care Consortium, Analysis and Data Systems Division, 2002.
10. Burney P, Suissa S, Soriano JB, et al. The pharmacoepidemiology of COPD: recent advances and methodological discussion. Eur Respir J 2003 43 (Suppl. S1 44.
11. Johansson G, Andreasson EB, Larsson PE, et al. Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics 2006 24 : 695 708.
12. Lofdahl CG, Ericsson A, Svensson K, et al. Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics 2005 23 : 365 75.
13. Oostenbrink JB, Rutten-van Molken MP, Al MJ, et al. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J 2004 23 : 241 9.
14. van der Palen J, Monninkhof E, van der Valk P, et al. Cost effectiveness of inhaled steroid withdrawal in outpatients with chronic obstructive pulmonary disease. Thorax 2006 61 : 29 33.
15. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002 19 : 217 24.
16. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002 19 : 209 16.
17. Garcia Ruiz AJ, Leiva Fernandez F, Martos Crespo F. Cost-effectiveness analysis of tiotropium compared to ipratropium and salmeterol. Arch Bronconeumol 2005 41 : 242 8.
18. Schramm W, Haake D, Brandt A. Economic value of tiotropium in the treatment of chronic obstructive pulmonary disease. Schweiz Rundsch Med Prax 2005 94 : 1803 10.
19. Wolinsky FD, Miller TR, An H, et al. Dual use of Medicare and the Veterans Health Administration: are there adverse health outcomes? BMC Health Serv Res 2006 6 : 131.